PIK3CA Mutation Detection
2004510
 
Ordering Recommendation
• Predicts response to anti-EGFR and AKT/mTOR pathway therapies in a variety of malignancies (eg, colorectal, ovarian, and breast cancer).
• Detects activating PIK3CA mutations in exons 9 and 20.
Mnemonic
PIK3CA
Methodology
Polymerase Chain Reaction/Pyrosequencing
Performed
Sun-Sat
Reported
12-14 days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
 
Collect
Tumor tissue.  
Specimen Preparation
Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. Transport block or 5 unstained 5 micron slides. (Min: 3 slides) Transport block and/or slide(s) in a tissue transport kit (ARUP supply # 47808) available online through eSupply using ARUP Connect™or contact ARUP Client Services at (800) 522-2787.  
Storage/Transport Temperature
Room temperature or refrigerated. Ship in cooled container during summer months.  
Unacceptable Conditions
No tumor in tissue. Specimens fixed/processed in alternative fixatives (alcohol, Prefer®) or heavy metal fixatives (B-4 or B-5). Decalcified specimens.  
Remarks
 
Stability
Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable  
Reference Interval
Interpretive Data
Refer to report.

See Compliance Statement B: www.aruplab.com/CS
Note
CPT Code(s)
88381; 81479
Components
Component Test Code*Component Chart Name
2002148Block ID
2004511PIK3CA Results
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, contact interface support at interface.support@aruplab.com.
Cross References
  • anti-EGFR therapy resistance
  • PIK3
  • PIK3CA
  • PIK3CA exons 9, 20